

cpt[®] **Assistant**

Official source for CPT coding guidance

SPECIAL EDITION: May Update

New COVID-19 Vaccine Codes: May Update

Based on the Food and Drug Administration's (FDA's) recent changes for the administration recommendations of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease 2019 [COVID-19]) messenger ribonucleic acid (mRNA) vaccines, the Current Procedural Terminology (CPT[®]) Editorial Panel (the Panel) has approved new vaccine administration codes 0171A and 0172A for the administration of a first and second dose of the Pfizer bivalent vaccine product (91317) for patients aged 6 months through 4 years; vaccine administration code 0151A for the administration of a single dose of the Pfizer bivalent vaccine product (91315) for patients aged 5 through 11 years; vaccine administration code 0121A for the administration of a single dose of the Pfizer bivalent vaccine product (91312); and vaccine administration codes 0141A and 0142A for the administration of the Moderna bivalent vaccine product (91314). These codes are effective as of April 18, 2023, following the FDA's announced

changes. **The original monovalent vaccines’ emergency use authorization (EUA) has been rescinded and those vaccines are no longer recommended for use. As a result, vaccine product and administration codes (see Table 1) for the original monovalent Pfizer and Moderna vaccines will be deleted at a future date, as this decision requires Panel action.**

Table 1. Pfizer and Moderna Monovalent Vaccine Product and Administration Codes To Be Deleted in the Future

Vaccine Code	Vaccine Administration Code(s)	Patient Age	Vaccine Manufacturer
91300 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3 mL dosage, diluent reconstituted, for intramuscular use	0001A (1st Dose) 0002A (2nd Dose) 0003A (3rd Dose) 0004A (Booster)	12 years and older	Pfizer, Inc
91305 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3 mL dosage, tris-sucrose formulation, for intramuscular use	0051A (1st Dose) 0052A (2nd Dose) 0053A (3rd Dose) 0054A (Booster)	12 years and older	Pfizer, Inc
91307 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 10 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation, for intramuscular use	0071A (1st Dose) 0072A (2nd Dose) 0073A (3rd Dose) 0074A (Booster)	5 years through 11 years	Pfizer, Inc

Vaccine Code		Vaccine Administration Code(s)	Patient Age	Vaccine Manufacturer
91308	Severe acute respiratory syndrome coronavirus 2 (SARS - CoV -2) (coronavirus disease [COVID -19]) vaccine, mRNA - LNP, spike protein, preservative free, 3 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation, for intramuscular use	0081A (1st Dose) 0082A (2nd Dose) 0083A (3rd Dose)	6 months through 4 years	Pfizer, Inc
91301	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 100 mcg/0.5 mL dosage, for intramuscular use	0011A (1st Dose) 0012A (2nd Dose) 0013A (3rd Dose)	12 years and older	Moderna, Inc
91306	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 50 mcg/0.25 mL dosage, for intramuscular use	0064A (Booster)	18 years and older	Moderna, Inc
91311	Severe acute respiratory syndrome coronavirus 2 (SARS - CoV -2) (coronavirus disease [COVID -19]) vaccine, mRNA - LNP, spike protein, preservative free, 25 mcg/0.25 mL dosage, for intramuscular use	0111A (1st Dose) 0112A (2nd Dose) 0113A (3rd Dose)	6 months through 5 years	Moderna, Inc
91309	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 50 mcg/0.5 mL dosage, for intramuscular use	0091A (1st Dose) 0092A (2nd Dose) 0093A (3rd Dose)	6 years through 11 years	Moderna, Inc
		0094A (Booster)	18 years and older	

In addition, the term “booster” will no longer be used and has been replaced with “additional dose.” This is the first step in streamlining the COVID-19 vaccine administration guidelines.

Lastly, edits have been made to the appropriate parentheticals of the bivalent COVID-19 vaccine codes to align with these recent changes.

To assist CPT code users in differentiating and reporting the available vaccine product codes and their affiliated vaccine administration codes appropriately, the American Medical Association (AMA) established a website that features timely updates of the Panel’s actions. The last COVID-19 update was in the *CPT® Assistant Special Edition: March Update (2023)* in which the Pfizer bivalent vaccine administration code (0174A) was discussed.

This issue of the *CPT® Assistant Special Edition* provides guidance on the appropriate use of the new Pfizer and Moderna bivalent vaccine administration codes based on these recent vaccine administration changes.

Immunization Administration for Vaccines/Toxoids

#● 0121A Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 30 mcg/0.3 mL dosage, tris-sucrose formulation; single dose

#▲ 0124A additional dose

▶ (Report 0121A, 0124A for the administration of vaccine 91312) ◀

▶ (Do not report 0121A, 0124A in conjunction with 91300, 91305, 91307, 91308, 91315, 91317) ◀

#● 0151A Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease

[COVID-19]) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 10 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation; single dose

#▲ 0154A additional dose

▶(Report 0151A, 0154A for the administration of vaccine 91315)◀

▶(Do not report 0151A, 0154A in conjunction with 91300, 91305, 91307, 91308, 91312, 91317)◀

#● 0171A Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 3 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation; first dose

#● 0172A second dose

#▲ 0173A third dose

#▲ 0174A additional dose

▶(Report 0171A, 0172A, 0173A, 0174A for the administration of vaccine 91317)◀

▶(Use 0174A in conjunction with 91317 when used as an additional dose administration of primary series for 91308, [ie, following administration of 0081A, 0082A, 0083A])◀

►(Do not report 0171A, 0172A, 0173A, 0174A in conjunction with 91300, 91305, 91307, 91308, 91312, 91315)◀

#● 0141A Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, bivalent, preservative free, 25 mcg/0.25 mL dosage; first dose

#● 0142A second dose

#▲ 0144A additional dose

►(Report 0141A, 0142A, 0144A for the administration of vaccine 91314)◀

►(Do not report 0141A, 0142A, 0144A in conjunction with 91301, 91306, 91311, 91309, 91313, 91316)◀

Given the volume of changes with the new vaccine administration recommendations and that there might be patients who have not been vaccinated yet, have already received one or more monovalent vaccines, or have already received one or more bivalent vaccines, Tables 2 and 3 have been created to provide guidance based on specific scenarios and by age group in which the appropriate vaccine product and vaccine administration codes may be reported. Note that these tables also include previously approved bivalent vaccine product and vaccine administration codes.

Table 2. Pfizer Bivalent Vaccines: Scenarios, Recommendations, and CPT Codes

Scenario	Recommendation	Codes
Patient aged 6 months through 4 years		
Patient is unvaccinated	Three doses of the bivalent vaccine	91317 0171A (first dose) 0172A (second dose) 0173A (third dose)
Patient received one dose of any monovalent vaccine	Two doses of the bivalent vaccine	91317 0172A (second dose) 0173A (third dose)
Patient received two doses of any monovalent vaccine	Single dose of the bivalent vaccine	91317 0173A (third dose)
Patient received three doses of any monovalent vaccine	Single dose of the bivalent vaccine	91317 0174A (additional dose)
Patient aged 5 through 11 years		
Patient is unvaccinated	Single dose of the bivalent vaccine	91315 0151A (single dose)
Patient received one or more doses of any monovalent vaccine	A single dose of the bivalent vaccine	91315 0151A (single dose)
Immunocompromised patient who received one dose of a bivalent vaccine	An additional dose of the bivalent vaccine	91315 0154A (additional dose)
Patient aged 12 years and older		
Patient is unvaccinated	A single dose of the bivalent vaccine	91312 0121A (single dose)
Patient received one or more doses of any monovalent vaccine	A single dose of the bivalent vaccine	91312 0121A (single dose)
Patients 65 years of age and older who received one dose of a bivalent vaccine	An additional dose of the bivalent vaccine	91312 0124A (additional dose)

Scenario	Recommendation	Codes
Immunocompromised patients who received one dose of a bivalent vaccine	An additional dose of the bivalent vaccine	91312 0124A (additional dose)

Table 3. Moderna Bivalent Vaccine: Scenarios, Recommendations, and CPT Codes

Scenario	Recommendation	Codes
Patient aged 6 months through 5 years		
Patient is unvaccinated	Two doses of the bivalent vaccine	91314 0141A (first dose) 0142A (second dose)
Patient received one dose of any monovalent vaccine	One dose of the bivalent vaccine	91314 0142A (second dose)
Patient received two doses of any monovalent vaccine	Additional dose of the bivalent vaccine	91316 0164A (additional dose)
Immunocompromised patient who received two doses of a monovalent vaccine or two doses of the bivalent vaccine	Additional dose of the bivalent vaccine	91314 0144A (additional dose)
Patient aged 6 through 11 years		
Patient is unvaccinated	Single dose of the bivalent vaccine	91314 0141A (first dose)
Patient received one or more doses of any monovalent vaccine	An additional dose of the bivalent vaccine	91314 0144A (additional dose)
Immunocompromised patient who received a dose of a bivalent vaccine	An additional dose of the bivalent vaccine	91314 0144A (additional dose)
Patient 12 years of age and older		
Patient is unvaccinated	A single dose of the bivalent vaccine	91313

Scenario	Recommendation	Codes
		0134A (additional dose)
Patient received one or more doses of any monovalent vaccine	A single dose of the bivalent vaccine	91313 0134A (additional dose)
Patients 65 years of age and older who received one dose of a bivalent vaccine	An additional dose of the bivalent vaccine	91313 0134A (additional dose)
Immunocompromised patients who received one dose of a bivalent vaccine	An additional dose of the bivalent vaccine	91313 0134A (additional dose)

As with previous COVID-19 vaccine administration codes, counseling is included as part of the administration visit and should not be reported separately. The physician or other qualified health care professional (QHP) should exercise clinical judgment to determine whether the administration of the vaccine product is appropriate for a given patient. More information on current guidance from the Centers for Disease Control and Prevention (CDC) regarding which patients should receive a COVID-19 vaccine is available at <https://www.cdc.gov/coronavirus/2019-ncov/vaccines/different-vaccines.html>. In addition, the April 18, 2023, FDA press release also provides guidance and links to fact sheets, which is available at <https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-changes-simplify-use-bivalent-mrna-covid-19-vaccines>.

Additional details on the vaccine coding structure and other pertinent information provided in multiple special editions of the *CPT® Assistant* for COVID-19 guidance are available at <https://www.ama-assn.org/practice-management/cpt/covid-19-cpt-coding-and-guidance>.

Table 4 is an excerpt from Appendix Q that highlights the addition of the new vaccine administration codes discussed in this article, as well as the language change from “booster dose” to “additional dose.” Refer to the full text of Appendix Q, which is available at <https://www.ama-assn.org/system/files/covid-19-immunizations-appendix-q-table.pdf>, to keep abreast of additional changes as they occur.

Table 4. Excerpt from Appendix Q: New Pfizer and Moderna Bivalent COVID-19 Vaccine Administration Codes

Vaccine Code		Vaccine Administration Code(s)	Patient Age
91312	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 30 mcg/0.3 mL dosage, tris-sucrose formulation, for intramuscular use	0121A (1 st Dose) 0124A (Additional Dose)	12 years and older
91315	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 10 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation, for intramuscular use	0151A (1 st Dose) 0154A (Additional Dose)	5 years through 11 years
91317	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 3 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation, for intramuscular use	0171A (1 st Dose) 0172A (2 nd Dose) 0173A (3 rd Dose) 0174A (Additional Dose)	6 months through 4 years
91313	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID]-19) vaccine, mRNA-LNP, spike protein, bivalent, preservative free, 50 mcg/0.5 mL dosage, for intramuscular use	0134A (Additional Dose)	12 years and older

Vaccine Code		Vaccine Administration Code(s)	Patient Age
91314	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease COVID-19) vaccine, mRNA-LNP, spike protein, bivalent, preservative free, 25 mcg/0.25 mL dosage, for intramuscular use	0141A (1st Dose) 0142A (2nd Dose) 0144A (Additional Dose)	6 months through 11 years
91316	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, bivalent, preservative free, 10 mcg/0.2 mL dosage, for intramuscular use	0164A (Additional Dose)	6 months through 5 years

The following clinical examples and procedural descriptions reflect typical clinical scenarios for which these new codes would be appropriately reported.

Typical Patient (0121A)

A 33-year-old individual seeks immunization against SARS-CoV-2 to decrease the risk of contracting this disease, consistent with evidence-supported guidelines. The individual is offered and accepts an intramuscular injection of SARS-CoV-2 vaccine for this purpose.

Description of Procedure (0121A)

The physician or other QHP reviews the patient's chart to confirm that vaccination to decrease the risk of COVID-19 is indicated. Counsel the patient on the benefits and risks of vaccination to decrease the risk of COVID-19 and obtain consent. Administer the bivalent first dose of the COVID-19 vaccine by intramuscular injection. Monitor the patient for any adverse reaction. Update the patient's immunization record (and registry when applicable) to reflect the vaccine administered.

Typical Patient (0141A)

A parent or guardian of a 7-year-old child seeks a bivalent first dose immunization against SARS-CoV-2 to decrease the risk of contracting this disease, consistent with evidence supported guidelines. The parent or guardian is offered and agrees to an intramuscular injection of SARS-CoV-2 vaccine for the child for this purpose.

Description of Procedure (0141A)

The physician or other QHP reviews the patient's chart to confirm that vaccination to decrease the risk of COVID-19 is indicated. Counsel the parent or guardian on the benefits and risks of vaccination to decrease the risk of COVID-19 and obtain consent. Administer the bivalent first dose of the bivalent COVID-19 vaccine by intramuscular injection. Monitor the patient for any adverse reaction. Update the patient's immunization record (and registry when applicable) to reflect the vaccine administered.

Typical Patient (0142A)

A parent or guardian of a 7-year-old child seeks a bivalent second dose immunization against SARS-CoV-2 to decrease the risk of contracting this disease, consistent with evidence supported guidelines. The parent or guardian is offered and agrees to an intramuscular injection of SARS-CoV-2 vaccine for the child for this purpose.

Description of Procedure (0142A)

The physician or other QHP reviews the patient's chart to confirm that vaccination to decrease the risk of COVID-19 is indicated. Counsel the parent or guardian on the benefits and risks of vaccination to decrease the risk of COVID-19 and obtain consent. Administer the bivalent second dose of the bivalent COVID-19 vaccine by intramuscular injection. Monitor the patient for any adverse reaction. Update the patient's immunization record (and registry when applicable) to reflect the vaccine administered.

Typical Patient (0151A)

A parent or guardian of a 7-year-old child seeks a bivalent first dose immunization against SARS-CoV-2 to decrease the risk of contracting this disease, consistent with evidence supported guidelines. The parent or guardian is offered and agrees to an intramuscular injection of SARS-CoV-2 vaccine for the child for this purpose.

Description of Procedure (0151A)

The physician or other QHP reviews the patient's chart to confirm that vaccination to decrease the risk of COVID-19 is indicated. Counsel the parent or guardian on the benefits and risks of vaccination to decrease the risk of COVID-19 and obtain consent. Administer the bivalent first dose of the bivalent COVID-19 vaccine by intramuscular injection. Monitor the patient for any adverse reaction. Update the patient's immunization record (and registry when applicable) to reflect the vaccine administered.

Typical Patient (0171A)

A parent or guardian of a 1-year-old child seeks bivalent immunization against SARS-CoV-2 to decrease the risk of contracting this disease, consistent with evidence supported guidelines. The parent or guardian is offered and agrees to an intramuscular injection of SARS-CoV-2 vaccine for the child for this purpose.

Description of Procedure (0171A)

The physician or other QHP reviews the patient's chart to confirm that vaccination to decrease the risk of COVID-19 is indicated. Counsel the parent or guardian on the benefits and risks of vaccination to decrease the risk of COVID-19 and obtain consent. Administer the first dose of the bivalent COVID-19 vaccine by intramuscular injection. Monitor the patient for any adverse reaction. Update the patient's immunization record (and registry when applicable) to reflect the vaccine administered.

Typical Patient (0172A)

A parent or guardian of a 1-year-old child seeks bivalent immunization against SARS-CoV-2 to decrease the risk of contracting this disease, consistent with evidence supported guidelines. The parent or guardian is offered and agrees to an intramuscular injection of SARS-CoV-2 vaccine for the child for this purpose.

Description of Procedure (0172A)

The physician or other QHP reviews the patient's chart to confirm that vaccination to decrease the risk of COVID-19 is indicated. Counsel the parent or guardian on the benefits and risks of vaccination to decrease the risk of COVID-19 and obtain consent. Administer the second dose of the bivalent COVID-19 vaccine by intramuscular injection. Monitor the patient for any adverse reaction. Update the patient's immunization record (and registry when applicable) to reflect the vaccine administered.

AMA Staff

Leslie W. Prellwitz, MBA, CCS, CCS-P, Managing Editor

Rejina Young, Editorial Assistant

Contributing Staff

Jennifer Bell; Kerri Fei; Karen O'Hara; Andrei G. Besleaga; Keisha Sutton-Asaya

Development and Production Staff

Elizabeth Goodman Duke; Lisa Chin-Johnson; Paige Downie, Laura Moreno

Orders: ama-assn.org/subscriptions

AMA website: www.ama-assn.org

The *CPT® Assistant Special Edition* information is designed to provide accurate, up-to-date coding information. We continue to make every reasonable effort to ensure the accuracy of the material presented. However, this publication does not replace the *CPT®* codebook; it serves only as a guide.

©2023 American Medical Association. All rights reserved. No part of this publication may be reproduced in any form without prior written permission of the publisher. *CPT®* is a registered trademark of the American Medical Association.